GLAND - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 4.2
| Stock Code | GLAND | Market Cap | 36,335 Cr. | Current Price | 2,202 ₹ | High / Low | 2,396 ₹ |
| Stock P/E | 27.6 | Book Value | 656 ₹ | Dividend Yield | 0.82 % | ROCE | 17.4 % |
| ROE | 12.8 % | Face Value | 1.00 ₹ | DMA 50 | 2,065 ₹ | DMA 200 | 1,874 ₹ |
| Chg in FII Hold | -0.29 % | Chg in DII Hold | 0.37 % | PAT Qtr | 420 Cr. | PAT Prev Qtr | 326 Cr. |
| RSI | 53.6 | MACD | 53.4 | Volume | 11,09,291 | Avg Vol 1Wk | 7,67,672 |
| Low price | 1,574 ₹ | High price | 2,396 ₹ | PEG Ratio | 1.59 | Debt to equity | 0.00 |
| 52w Index | 76.4 % | Qtr Profit Var | 45.0 % | EPS | 78.9 ₹ | Industry PE | 32.1 |
GLAND Pharma shows strong fundamentals with ROCE (17.4%) and ROE (12.8%), debt-free balance sheet, and robust quarterly profit growth (+45%). The current price (₹2,202) is above both the 50 DMA (₹2,065) and 200 DMA (₹1,874), confirming bullish momentum. RSI at 53.6 and MACD at 53.4 indicate positive momentum, while trading volume is significantly higher than the weekly average, reflecting strong participation. However, the PEG ratio of 1.59 suggests growth is slightly expensive. Overall, GLAND is a favorable candidate for swing trading.
🎯 Optimal Entry Price
Entry around ₹2,150–2,180 is favorable, aligning with support near the 50 DMA.
📈 Exit Strategy
If already holding, consider exiting near ₹2,350–2,380 (resistance zone close to recent highs). A stop-loss below ₹2,100 is advisable to manage risk.
✅ Positive
- 📌 Strong quarterly PAT growth from ₹326 Cr. to ₹420 Cr. (+45%).
- 📌 EPS of ₹78.9 with reasonable P/E of 27.6 compared to industry average of 32.1.
- 📌 Debt-free balance sheet ensures financial stability.
- 📌 DII holdings increased (+0.37%), showing domestic institutional confidence.
- 📌 Volume significantly higher than weekly average, reflecting strong market interest.
⚠️ Limitation
- 📌 PEG ratio of 1.59 suggests growth is slightly expensive.
- 📌 FII holdings decreased (-0.29%), showing reduced foreign investor confidence.
- 📌 Current price is near 76% of 52-week high, limiting upside potential.
📰 Company Negative News
- 📌 No major negative news reported, but valuation concerns exist due to PEG ratio and reduced FII interest.
🌟 Company Positive News
- 📌 Strong quarterly profit growth supports earnings stability.
- 📌 Domestic institutional investors increasing stake shows confidence in long-term performance.
🏭 Industry
- 📌 Industry P/E of 32.1 is slightly higher than GLAND’s 27.6, suggesting relative undervaluation.
- 📌 Pharmaceutical sector remains resilient with strong demand for healthcare products.
🔎 Conclusion
GLAND Pharma is fundamentally strong with bullish technical signals. It is a good candidate for swing trading with entry near ₹2,150–2,180 and exit around ₹2,350–2,380. A strict stop-loss below ₹2,100 should be maintained to manage risk effectively.
Would you like me to extend this with a sector overlay analysis or a peer benchmarking comparison to contextualize GLAND’s swing trade potential against its industry peers?